Evidence map›Paper›PMID 37873495›Full record

ArticleOncoTargets and therapy2023

CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma.

Zhixing Xu, Haitao Xu, Xi Chen, Xiaobing Huang, Jintao Tian, Jinxi Zhao, Bohu Liu, Fengcai Shi, Jin Wu, Jun Pu

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zhixing Xu *Department of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Haitao Xu *Department of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Xi Chen *Department of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Xiaobing HuangDepartment of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Jintao TianDepartment of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Jinxi ZhaoDepartment of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Bohu LiuDepartment of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Fengcai ShiDepartment of Neurosurgery, The Pu'er People's Hospital, Pu'er, 665000, People's Republic of China.
Jin WuDepartment of Neurosurgery, The Pu'er People's Hospital, Pu'er, 665000, People's Republic of China.
Jun PuDepartment of Neurosurgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650223, People's Republic of China.
Kunming Medical University · CNPuer University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The Coiled-coil domain-containing proteins (CCDCs) are expressed in many cancers, but the role of Coiled-coil domain-containing protein 103 (CCDC103) in cancers remains unclear. Further investigations are necessary to ascertain its diagnostic significance and understand its biological function in cancers. This study aims to elucidate the biological functionalities of CCDC103 in glioma and evaluate the correlation between CCDC103 expression with glioma progression. Methods: Clinical data on glioma patients were acquired from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), and the Gene Expression Omnibus (GEO). The evaluation encompassed the examination of correlations between CCDC103 expression, pathological characteristics, and clinical outcomes. Furthermore, the analysis included the assessment of the correlations between CCDC103 expression and immune cell infiltration as well as glioma progression. Results: Gliomas have higher levels of CCDC103 expression than the para-carcinoma tissues. Poorer prognosis, unfavorable histological characteristics, the absence of IDH gene mutations, and the absence of chromosome 1p and 19q deletions were all associated with higher expression of CCDC103 in gliomas. In addition to patient age, tumor grade, the absence of IDH mutations, and the absence of chromosome 1p and 19q deletions, univariate and multivariate Cox analyses showed that CCDC103 expression was independently prognostic of overall survival, disease-free survival, and progression-free survival in patients with glioma. Furthermore, tumor infiltration of B cells, neutrophils, macrophages, and dendritic cells were all linked with elevated expression of CCDC103. High CCDC103 expression was linked to immune response-related signaling pathways and cell proliferation, according to gene set enrichment analysis (GSEA). Notably, the knockdown of CCDC103 in glioma cell lines resulted in a significant reduction in cell proliferation and migration. Conclusion: The correlation between CCDC103 expression and both glioma progression and immune cell infiltration implies that CCDC103 expression holds promise as a valuable prognostic biomarker for glioma.

Indexed as

biomarkerCCDC103gliomaimmune infiltrationprognosis

Identifiers

PMID37873495
PMCPMC10590567
OpenAlexW4387745420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.